Yoon Sim Yap
YOU?
Author Swipe
View article: Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting
Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting Open
Introduction: Trastuzumab deruxtecan (T-DXd) has revolutionised treatment for metastatic breast cancer (MBC). While effective, its high cost and toxicities, such as fatigue and nausea, pose challenges. Method: Medical records from the Join…
View article: Risking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it?
Risking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it? Open
View article: Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold
Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold Open
The Ser/Thr kinase RAF, particularly BRAF isoform is a dominant target of oncogenic mutations and many mutations have been identified in various cancers. However, how these mutations except V600E evade the regulatory machinery of RAF prote…
View article: Effects of supplemental chitosan on serum lipid levels: A systematic review and meta-analysis of randomised controlled trials
Effects of supplemental chitosan on serum lipid levels: A systematic review and meta-analysis of randomised controlled trials Open
View article: Supplementary Information from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Information from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
The supplementary information describes the procedures used to assess circulating tumor DNA using the Novartis PanCancer gene panel.
View article: Supplementary Figure 4 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 4 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 4 shows the baseline tumor mutation status in each arm for those who achieved a defined clinical benefit on treatment versus those who did not.
View article: Supplementary Tables from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Tables from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
The supplementary tables file contains four individual tables detailing: exclusions from the dose-determining set, treatment-related serious AEs, steady-state LSZ102 PK parameters, and a summary of best overall responses by treatment arm.
View article: Supplementary Figure 3 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 3 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 3 shows progression-free survival (Kaplan-Meier) in each treatment arm.
View article: Supplementary Figure 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 2 shows on-treatment estrogen receptor H-score changes from baseline in the combination treatment arms.
View article: Data from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Data from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Purpose:Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and combination use in a phase I study.Patients and Methods:A phase I,…
View article: Supplementary Figure 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 1 shows LSZ102 dose proportionality analyses for fasted, once-daily administration
View article: Supplementary Figure 6 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 6 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 6 shows exploratory multivariable predictors of disease progression in each treatment arm.
View article: Supplementary Figure 7 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 7 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 7 shows progression-free survival (Kaplan-Meier) by baseline ESR1 and PIK3CA mutation status in both combination treatment arms.
View article: Supplement 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplement 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplement 1 contains the trial protocol.
View article: Supplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplementary figure 5 shows baseline versus end-of-treatment tumor mutation status among those who achieved a defined clinical benefit on treatment.
View article: Supplement 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplement 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer Open
Supplement 2 contains the trial statistical analysis plan.
View article: Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study
Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study Open
ABCCG-Asian patients with breast cancer <40 years old with HR+/HER2- subtypes were more likely to have worse survival outcomes than their mid-age counterparts. Our study highlights the poorer prognosis of young patients and underscores the…
View article: A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer Open
View article: Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Open
PURPOSE A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor–…
View article: Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study
Outcomes in Nonmetastatic Hormone Receptor–Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study Open
Background: Although considered a favorable subtype, pure mucinous breast cancer (PMBC) can recur, and evidence for adjuvant therapy is limited. We aimed to compare outcomes of nonmetastatic PMBC with invasive ductal carcinoma (IDC) and in…
View article: Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study Open
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 …
View article: Supplemental Table 3 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Table 3 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Table 3. Multivariable analysis of treatment benefit by subtype
View article: Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Figure 1: CONSORT diagrams of the MONALEESA (ML) trials.
View article: Data from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Data from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Purpose:The MONALEESA-2, -3, -7 trials demonstrated statistically significant and clinically meaningful progression-free survival and overall survival (OS) benefits with ribociclib plus endocrine therapy (ET) versus ET alone in hormone rec…
View article: Supplemental Table 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Table 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Table 1. Representativeness of study participants
View article: Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Figure 1: CONSORT diagrams of the MONALEESA (ML) trials.
View article: Supplemental Table 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Table 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Table 1. Representativeness of study participants
View article: Data from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Data from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Purpose:The MONALEESA-2, -3, -7 trials demonstrated statistically significant and clinically meaningful progression-free survival and overall survival (OS) benefits with ribociclib plus endocrine therapy (ET) versus ET alone in hormone rec…
View article: Supplemental Table 2 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Table 2 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Table 2. Patient characteristics by subtype
View article: Supplemental Table 2 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7
Supplemental Table 2 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 Open
Supplemental Table 2. Patient characteristics by subtype